Effexor XR is a brand name of venlafaxine, approved by the FDA in the following formulation(s):
EFFEXOR XR (venlafaxine hydrochloride - capsule, extended release; oral)
Manufacturer: WYETH PHARMS INC
Approval date: October 20, 1997
Strength(s): EQ 150MG BASE [RLD][AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Has a generic version of Effexor XR been approved?
A generic version of Effexor XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Effexor XR and have been approved by the FDA:
venlafaxine hydrochloride capsule, extended release; oral
Manufacturer: AUROBINDO PHARMA LTD
Approval date: April 14, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: May 6, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: MYLAN
Approval date: June 1, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: ORCHID HLTHCARE
Approval date: July 11, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: TEVA
Approval date: June 28, 2010
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: TORRENT PHARMS LLC
Approval date: June 1, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: VALEANT INTL
Approval date: April 15, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: WOCKHARDT
Approval date: April 14, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: ZYDUS PHARMS USA INC
Approval date: April 14, 2011
Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Effexor XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Venlafaxine for the treatment of generalized anxiety disorder
Patent 5,916,923
Issued: June 29, 1999
Inventor(s): Rudolph; Richard L. & Upton; G. Virginia
Assignee(s): American Home Products Corporation
This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia iervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, aakyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.Patent expiration dates:
- June 28, 2013✓
- December 28, 2013✓✓
- June 28, 2013
Extended release formulation of venlafaxine hydrochloride
Patent 6,274,171
Issued: August 14, 2001
Inventor(s): Sherman; Deborah M. & Clark; John C. & Lamer; John U. & White; Steven A.
Assignee(s): American Home Products Corporation
This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Patent expiration dates:
- March 20, 2017
- September 20, 2017✓
- March 20, 2017
Treatments using venlafaxine
Patent 6,310,101
Issued: October 30, 2001
Inventor(s): Rudolph; Richard L. & Derivan; Albert T. & Muth; Eric A. & Upton; G. Virginia
Assignee(s): American Home Products Corporation
This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.Patent expiration dates:
- June 28, 2013✓
- June 28, 2013
Extended release formulation of venlafaxine hydrochloride
Patent 6,403,120
Issued: June 11, 2002
Inventor(s): Deborah M.; Sherman & John C.; Clark & John U.; Lamer & Steven A.; White
Assignee(s): Wyeth
This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Patent expiration dates:
- March 20, 2017✓
- March 20, 2017✓
- September 20, 2017✓✓
- September 20, 2017✓✓
- March 20, 2017
Extended release formulation of venlafaxine hydrochloride
Patent 6,419,958
Issued: July 16, 2002
Inventor(s): Deborah M.; Sherman & John C.; Clark & John U.; Lamer & Steven A.; White
Assignee(s): Wyeth
This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Patent expiration dates:
- March 20, 2017✓
- March 20, 2017✓
- September 20, 2017✓✓
- September 20, 2017✓✓
- March 20, 2017
Treatment using venlafaxine
Patent 6,444,708
Issued: September 3, 2002
Inventor(s): Richard L.; Rudolph & Albert T.; Derivan & G. Virginia; Upton
Assignee(s): Wyeth
This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: in which A is a moiety of the formula where the dotted line represents optional unsaturation; R1 is hydrogen or alkyl; R2 is alkyl; R4 is hydrogen, alkyl, formyl, or alkanol; R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.Patent expiration dates:
- June 28, 2013✓
- December 28, 2013✓✓
- June 28, 2013
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- December 14, 2010 - LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
See also...
- Effexor XR Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Effexor XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Effexor XR Consumer Information (Cerner Multum)
- Effexor-XR Advanced Consumer Information (Micromedex)
- Venlafaxine Consumer Information (Drugs.com)
- Venlafaxine Consumer Information (Wolters Kluwer)
- Venlafaxine Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Venlafaxine Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Venlafaxine Consumer Information (Cerner Multum)
- Venlafaxine Advanced Consumer Information (Micromedex)
- Venlafaxine Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment